Doxycycline in Type II Diabetes

StatusCompleted
PhasePhase 1/2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed Show 4 more changesShow less
    • Study completion date changed from estimate of Apr 20, 2026 to Mar 20, 2026
    • Site details revised
    • Publications: details revised at 1 of 1 entry
    • Eligibility criteria expanded, about 2 words
  2. Primary completion date: Mar 20, 2025 to Mar 20, 2026
    • Study completion date: Apr 20, 2025 to Apr 20, 2026
    v3
  3. Trial status: Not Yet Recruiting to Recruitingv2
  4. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Mostafa Bahaa
14 trials monitored
See 1 trial at risk
Diabetes
5,141 trials monitored
See 246 trials at risk
Type 2 Diabetes
2,257 trials monitored
See 120 trials at risk
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease characterized by hyperglycemia, weight loss, and cardio-metabolic complications. T2DM develops due to the progression of insulin resistance (IR), impairment of insulin insensitivity, and failure of the pancreatic β-cells to release sufficient amount of insulin in response to glucose burden
Trial Details
NCT Number NCT06329882
Lead Sponsor Mostafa Bahaa
Conditions
(from sponsor)		 Diabetes Mellitus, Type 2
Related terms Diabetes Mellitus, Type 2
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov